CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care
CytoSorb now commercially available in Korea – one of the leading economies in Asia - to treat cytokine storm and other illnesses in critically-ill and cardiac surgery patients MONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunot...
2021-01-19 20:08
6117
Frost & Sullivan Lauds CytoSorbents for Leading the Critical Care Immunotherapy Segment with its Novel Blood Purification Solution, CytoSorb®
By controlling dangerous inflammation, CytoSorb® is enabling superior outcomes in critically-ill patients, with reduced overall costs of intensive care in its sights LONDON, Aug. 2, 2017 /PRNewswire/ -- Based on its recent analysis of the blood purification market, Frost & Sullivan recognizes Cy...
2017-08-02 19:00
2974
